RECURRENT BURKITT LYMPHOMA

Clinical trials for RECURRENT BURKITT LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT BURKITT LYMPHOMA trials appear

Sign up with your email to follow new studies for RECURRENT BURKITT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1 Not yet finished but already full! 5 Completed 1

Can a Two-Pronged antibody boost chemo against tough lymphomas?

Disease control Not yet recruiting

This trial tests whether adding the bispecific antibody glofitamab to standard chemoimmunotherapy can improve outcomes for people with Burkitt lymphoma or high-grade B-cell lymphoma with MYC and BCL2 rearrangements. These are fast-growing cancers that can be hard to treat. The st…

Matched conditions: RECURRENT BURKITT LYMPHOMA

Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jul 29, 2026 00:00 UTC

RECURRENT BURKITT LYMPHOMA

Get alerted when new RECURRENT BURKITT LYMPHOMA trials appear

Can a Two-Pronged antibody boost chemo against tough lymphomas?